osimertinib,blu-945
blueprint medicines,astrazeneca,roche
['lung', 'blu-945', 'osimertinib', 'symphony']
at #asco23, our presented findings from his phase i/ii symphony study, which is showing that blu-945, a novel therapy targeting mutant egfr, can reduce circulating cancer dna, alone or with osimertinib. learn more: #lungcancer #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789